Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

IDE574

Small molecule · Inhibitor of KAT6A (MOZ, MYST3) (KAT6A), KAT6B (MORF, MOZ2, MYST4) (KAT6B) and KAT7 (HBO1, MYST2) (KAT7) · developed by IDEAYA Biosciences

Phase 1 Most advanced trial
IDYA Developer
1 Registered trials

What is IDE574?

IDE574 is an orally bioavailable small molecule that inhibits the histone acetyltransferases KAT6A, KAT6B and KAT7, reducing acetylation of histones and other nonhistone substrates. It is being studied in ER-positive, HER2-negative breast cancer, non-small cell lung cancer, castration-resistant prostate cancer and microsatellite stable colorectal carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
KAT6A (MOZ, MYST3) (KAT6A), KAT6B (MORF, MOZ2, MYST4) (KAT6B), KAT7 (HBO1, MYST2) (KAT7)
Mechanism
Inhibitor of KAT6A (MOZ, MYST3) (KAT6A), KAT6B (MORF, MOZ2, MYST4) (KAT6B) and KAT7 (HBO1, MYST2) (KAT7)
Pathways
histone acetylation, gene expression regulation, cell cycle regulation
Therapy area
Oncology
Developer
IDEAYA Biosciences (IDYA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07540572 Phase 1 Cancer Recruiting IDYA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-resistant Prostate Cancer (CRPC)ER+, HER 2- Breast CancerMicrosatellite Stable (MSS) Colorectal CarcinomaNon-small Cell Lung Cancer (NSCLC)

Other drugs acting on KAT6A / KAT6B / KAT7

More from IDEAYA Biosciences

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IDYA page.

Follow IDYA, the company behind IDE574

See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IDYA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.